Edgewise Therapeutics will sell its experimental muscular dystrophy drug and related business to Servier for up to $2.65 billion. The deal is a meaningful monetization event for Edgewise and highlights continued M&A interest in biotech assets. The transaction should be supportive for Edgewise shares and relevant to the broader healthcare M&A landscape.
Edgewise Therapeutics will sell its experimental muscular dystrophy drug and related business to Servier for up to $2.65 billion. The deal is a meaningful monetization event for Edgewise and highlights continued M&A interest in biotech assets. The transaction should be supportive for Edgewise shares and relevant to the broader healthcare M&A landscape.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.45
Ticker Sentiment
